All News
Filter News
Found 198 articles
-
Chiesi Global Rare Diseases Announces Co-Development Agreement with Aliada Therapeutics to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders
8/15/2023
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, announced a co-development agreement with Aliada Therapeutics, a biotechnology company developing a novel blood-brain barrier -crossing platform technology to address challenging disease areas with high unmet need.
-
Chiesi Group Mid-Year Financial Results Demonstrate Strong Growth for 2023
8/8/2023
Chiesi USA, Inc., a Cary-based specialty pharmaceutical company, announced that Chiesi Group is continuing to experience major growth this year.
-
Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results
8/7/2023
Protalix BioTherapeutics, Inc. reported financial results for the second quarter ended June 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.
-
Chiesi USA CEO Appointed to ASHP Foundation Board of Directors
7/20/2023
Chiesi USA, Inc., a Cary-based specialty pharmaceutical company, announced that Jon Zwinski, CEO and General Manager at Chiesi USA, has been appointed to the American Society of Health-System Pharmacists Foundation Board of Directors.
-
Bioasis Provides Corporate Update and Announces Suspension of Operations
6/20/2023
BIOASIS TECHNOLOGIES INC., a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier and the treatment of central nervous system disorders in areas of high unmet medical need, provided an update on its financial condition and operations.
-
Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties
6/20/2023
Santhera Pharmaceuticals announces that it has signed an exclusive license and collaboration agreement for vamorolone in North America with Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on novel medicines for patients living with rare diseases.
-
Chiesi USA Partners with Smith Anderson to Host 1L Excellence in Diversity Fellow this Summer
6/12/2023
Chiesi USA, Inc., a Cary-based specialty pharmaceutical company, in partnership with Smith Anderson, a Triangle-based full-service business and litigation law firm, will host Cecilia Poston, the firm’s 2023 1L Excellence in Diversity Fellow for three weeks this month.
-
Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease
6/8/2023
Protalix BioTherapeutics, Inc. today announced it will host an in-person KOL breakfast in New York on Tuesday, June 27, 2023 at 8:00 a.m. Eastern Daylight Time (EDT), with presentations beginning at 8:30 a.m. EDT.
-
Protalix BioTherapeutics Issues Letter to Stockholders
5/30/2023
Protalix BioTherapeutics, Inc. today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community.
-
Enzyme Replacement Therapy Market (Enzyme Type, Therapeutic Conditions, Route of Administration) Worth $15.18 Billion by 2028 at 6.8% CAGR Led by Hospitals Segment | The Insight Partners
5/26/2023
The Insight Partners published latest research study on “Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Enzyme Type
-
Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases
5/18/2023
Protalix BioTherapeutics, Inc. today announced that it is eligible to receive a $20 million milestone payment from its commercial partner, Chiesi Global Rare Diseases, a business unit of the Chiesi Group.
-
Elfabrio’s label contains a boxed warning for hypersensitivity reactions, such as anaphylaxis, and recommends that medical support measures should be on standby when administering the treatment.
-
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease
5/10/2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. announced that the U.S. Food and Drug Administration has approved ELFABRIO in the United States for the treatment of adult patients with Fabry disease.
-
The FDA's agenda includes an advisory committee meeting for Sarepta's delandistrogene moxeparvovec, which, if approved, would become the first gene therapy for Duchenne muscular dystrophy.
-
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
5/5/2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. announced that the European Commission has granted marketing authorization to PRX-102 in the European Union for the treatment of adult patients with Fabry disease.
-
Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results
5/4/2023
Protalix BioTherapeutics, Inc. reported financial results for the first quarter ended March 31, 2023 and provided a business update on recent regulatory, clinical and corporate developments.
-
Chiesi Global Rare Diseases Announces U.S. Networkwide Sponsorship of BioInnovation Labs
4/18/2023
Chiesi Global Rare Diseases announced a U.S. Networkwide Sponsorship of BioInnovation Labs, the leading developer and operator of life science coworking spaces with 12 active facilities and a growing network in the U.S. and internationally.
-
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
4/12/2023
Chiesi Farmaceutici S.p.A. announced the completion of the acquisition of Amryt Pharma Plc, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases.
-
2022 for Chiesi: The Group’s international growth continues
4/11/2023
The growth of Chiesi, a research-oriented international biopharmaceutical group headquartered in Parma and 31 Affiliates worldwide, continues.
-
Chiesi's international growth continues
4/5/2023
Chiesi, the research-oriented international biopharmaceutical group headquartered in Parma, recorded a turnover of €2,749 billion in 2022, an increase of 13.6% from 2021.